These data led the independent data and basic safety monitoring committee to suggest unblinding of the study data, with sufferers in the placebo group getting abiraterone acetate if indeed they met the criteria for crossover treatment specific in process amendment 3.0 . All of the secondary end points analyzed provided support for the superiority of abiraterone acetate over placebo , including the confirmed PSA response rate , the objective response rate based on RECIST among patients with measurable disease at baseline , time to PSA progression , and median progression-free survival based on radiographic evidence .Copyright 2007 Advisory Board Kaiser and Organization Family Foundation. All rights reserved. Related StoriesInnovative single-use torque instruments utilize difficult polycarbonate from BayerPreventing falls in treatment homes: an interview with Professor Pip LoganWHO focused on helping Nepal deliver health care to its residents, says WHO South-East Asia Regional Director.
53 talk about a needle & HIV risk because of a clinic blunder By Dr Ananya Mandal, MD Over 50 sufferers at a private radiology clinic received blood tests utilizing a needle device meant for single-patient make use of. Authorities have launched an investigation into the matter.